CVRx Inc (CVRX)

Currency in USD
0.6110
-0.0020(-0.33%)
Closed·
0.61100.0000(0.00%)
·
CVRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.57080.6870
52 wk Range
0.566310.2800
Key Statistics
Prev. Close
0.611
Open
0.64
Day's Range
0.5708-0.687
52 wk Range
0.5663-10.28
Volume
637.32K
Average Vol. (3m)
755.94K
1-Year Change
-93.3946%
Book Value / Share
0.52
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CVRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.6500
Upside
+170.05%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

CVRx Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
5 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 1.6500
(+170.05% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Hold1.50+145.50%4.00MaintainNov 09, 2026
Craig-Hallum
Hold1.25+104.58%4.00MaintainNov 06, 2026
Lake Street
Hold1.50+145.50%3.50MaintainNov 06, 2026
Piper Sandler
Hold1.50+145.50%4.00MaintainNov 06, 2026
Canaccord
Hold2.00+227.33%5.00DowngradeNov 06, 2026

CVRx Inc SWOT Analysis


Analyst Outlook
Discover why analysts remain optimistic about CVRx's long-term prospects, with price targets ranging from $14 to $23, despite short-term challenges.
Market Expansion
Learn how CVRx is increasing its market presence, with 227 active implanting centers and strategic adjustments to sales territories for optimized growth.
Financial Pulse
Despite recent revenue shortfalls, CVRx maintains robust gross margins of 83.75% and achieved 30.53% revenue growth over the last twelve months.
Barostim Breakthrough
Explore CVRx's innovative heart failure treatment, Barostim, and its potential to revolutionize the $3.7 billion HFrEF market with impressive clinical outcomes.
Read full SWOT analysis

CVRx Inc Earnings Call Summary for Q2/2026

  • CVRx Q2 revenue rose 16% YoY to $15.7M, beating estimates, but shares plunged 33% after-hours on reduced 2026 guidance to $58M-$60M.
  • Gross margin improved to 87% from 84%, though net loss narrowed only slightly to $14M as sales force turnover hampered territory productivity.
  • Management attributed guidance cut to execution issues, not demand weakness, citing high rep turnover and slow onboarding in key regions.
  • Q3 revenue guidance of $13.5M-$14.5M signals sequential decline; company maintains 18 months cash runway with $64.6M on hand plus $40M credit.
  • CVRx faces DOJ civil investigation into sales practices while banking on BENEFIT-HF trial results and Medicare reimbursement gains as growth catalysts.
Last Updated: 08/06/2026, 05:09 PM
Read Full Transcript

Earnings

Latest Release
Nov 05, 2026
EPS / Forecast
-0.52 / -0.50
Revenue / Forecast
13.8M / 13.94M
EPS Revisions
Last 90 days

CVRX Income Statement

Compare CVRX to Peers and Sector

Metrics to compare
CVRX
Peers
Sector
Relationship
P/E Ratio
−0.3x−8.5x−0.2x
PEG Ratio
−0.33−0.170.00
Price / Book
1.3x5.6x2.6x
Price / LTM Sales
0.3x2.8x2.7x
Upside (Analyst Target)
170.0%101.7%68.5%
Fair Value Upside
Unlock−10.1%11.5%Unlock

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.59M9.08%1.59M
Other Institutional Investors
18.10M63.55%11.10M
Public Companies & Retail Investors
7.80M27.37%4.78M
Total
28.49M100.00%17.46M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Johnson & Johnson Innovation - JJDC, Inc.14.13%4,024,8612,467
New Enterprise Associates, Inc.6.86%1,954,4401,198

People Also Watch

3.175
CCOI
-14.88%
56.730
LQDA
+0.64%
1.795
LFMD
-2.97%
3.000
CABO
+1.35%
49.89
CRWV
+0.02%

FAQ

What Is the CVRx (CVRX) Stock Price Today?

The CVRx stock price today is 0.6110 USD.

What Stock Exchange Does CVRx Trade On?

CVRx is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for CVRx?

The stock symbol for CVRx is "CVRX."

What Is the CVRx Market Cap?

As of today, CVRx market cap is 17.6600M USD.

What Is CVRx's Earnings Per Share (TTM)?

The CVRx EPS (TTM) is -2.00.

When Is the Next CVRx Earnings Date?

CVRx will release its next earnings report on Feb 17, 2027.

From a Technical Analysis Perspective, Is CVRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has CVRx Stock Split?

CVRx has split 0 times.

How Many Employees Does CVRx Have?

CVRx has 223 employees.

What is the current trading status of CVRx (CVRX)?

As of Nov 18, 2026, CVRx (CVRX) is trading at a price of 0.6110 USD, with a previous close of 0.6110 USD. The stock has fluctuated within a day range of 0.5708 USD to 0.6870 USD, while its 52-week range spans from 0.5663 USD to 10.2800 USD.

What Is CVRx (CVRX) Price Target According to Analysts?

The average 12-month price target for CVRx is 1.6500 USD, with a high estimate of 2 USD and a low estimate of 1.25 USD. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +170.05% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.